title: Hemolytic uremic syndrome with ischemic glomerulonephropathy and obliterative vasculopathy in a systemic sclerosis patient treated with cyclosporine-A.
abstract: Hemolytic uremic syndrome (HUS) is not a commonly reported complication in post-transplantation patients treated with cyclosporine-A (CSA), and is extremely rare in systemic sclerosis (SSc) patients treated with this drug. CSA may contribute to the development of chronic ischemic glomerulonephropathy and vasculopathy, features not easily distinguished from SSc-related nephropathy. Here, we describe a 41-year-old Chinese man with diffuse-type SSc treated with CSA who developed thrombocytopenia, acute renal failure and hemolytic anemia and was diagnosed with HUS. Renal function and thrombocytopenia improved gradually after intensive treatment of plasma exchange (PE) and high-dose steroid therapy. After PE, renal biopsy showed ischemic glomerulonephropathy and obliterative vasculopathy. This case illustrates that PE can improve the hematological disorders and characteristic renal changes of HUS in SSc patients treated with CSA. However, this therapy may not be effective in normalizing serum creatinine level in SSc patients once CSA has triggered the normal kidney to develop glomerulonephropathy and vasculopathy with ischemic and sclerotic changes.
authors.affiliation: Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, 201, Sec2, Shih-Pai Road, Taipei, 11217, Taiwan.
authors.forename: Wei-Sheng
authors.initials: WS
authors.lastname: Chen
authors.forename: An-Hang
authors.initials: AH
authors.lastname: Young
authors.forename: Hon-Pin
authors.initials: HP
authors.lastname: Wang
authors.forename: De-Feng
authors.initials: DF
authors.lastname: Huang
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced / Q000503:physiopathology; D000328:Adult; D000743:Anemia, Hemolytic / Q000139:chemically induced / Q000503:physiopathology; D018501:Antirheumatic Agents / Q000009:adverse effects; D044466:Asian People; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects*; D015433:Glomerulonephritis, Membranous / Q000139:chemically induced* / Q000503:physiopathology; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D007511:Ischemia / Q000139:chemically induced* / Q000503:physiopathology; D007668:Kidney / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D008297:Male; D010951:Plasma Exchange; D012077:Renal Artery / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D013256:Steroids / Q000627:therapeutic use; D013624:Taiwan; D013921:Thrombocytopenia / Q000139:chemically induced / Q000503:physiopathology; D014657:Vasculitis / Q000139:chemically induced* / Q000503:physiopathology
chemical_list: D018501:Antirheumatic Agents; D013256:Steroids; D016572:Cyclosporine; D003404:Creatinine